Liquidia (NASDAQ:LQDA) Upgraded at Wall Street Zen

Liquidia (NASDAQ:LQDA) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

LQDA has been the topic of a number of other research reports. Jefferies Financial Group boosted their price target on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, January 13th. Raymond James Financial reissued a “strong-buy” rating on shares of Liquidia in a research note on Thursday. HC Wainwright boosted their target price on shares of Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday. Wells Fargo & Company upped their price target on shares of Liquidia from $31.00 to $44.00 and gave the company an “overweight” rating in a research report on Friday. Finally, BTIG Research increased their price target on Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.00.

Liquidia Price Performance

Shares of LQDA opened at $36.03 on Friday. The business has a 50-day moving average of $37.10 and a 200-day moving average of $30.89. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The company has a market capitalization of $3.13 billion, a price-to-earnings ratio of -43.41, a price-to-earnings-growth ratio of 0.60 and a beta of 0.52. Liquidia has a 1 year low of $11.26 and a 1 year high of $46.67.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The company had revenue of $92.02 million during the quarter. Liquidia had a negative net margin of 43.53% and a negative return on equity of 237.79%. The company’s revenue was up 3072.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Liquidia will post -1.51 earnings per share for the current year.

Insider Buying and Selling

In other Liquidia news, General Counsel Russell Schundler sold 27,289 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the transaction, the general counsel owned 579,394 shares in the company, valued at approximately $21,686,717.42. This represents a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 66,610 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $2,493,212.30. Following the completion of the transaction, the chief executive officer directly owned 1,037,528 shares in the company, valued at $38,834,673.04. This trade represents a 6.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 212,534 shares of company stock worth $7,964,719 over the last quarter. Corporate insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. bought a new position in Liquidia in the 4th quarter valued at about $25,000. Covestor Ltd increased its holdings in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in Liquidia during the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC purchased a new stake in shares of Liquidia in the third quarter worth approximately $34,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Liquidia in the second quarter worth approximately $25,000. 64.54% of the stock is owned by institutional investors.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).